ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

PURPOSE: Enzalutamide, a potent androgen-receptor inhibitor, has demonstrated significant benefits in metastatic and nonmetastatic castration-resistant prostate cancer. We evaluated the efficacy and safety of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC). METHODS: ARCHES (Clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Armstrong, Andrew J., Szmulewitz, Russell Z., Petrylak, Daniel P., Holzbeierlein, Jeffrey, Villers, Arnauld, Azad, Arun, Alcaraz, Antonio, Alekseev, Boris, Iguchi, Taro, Shore, Neal D., Rosbrook, Brad, Sugg, Jennifer, Baron, Benoit, Chen, Lucy, Stenzl, Arnulf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839905/
https://www.ncbi.nlm.nih.gov/pubmed/31329516
http://dx.doi.org/10.1200/JCO.19.00799

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839905/
https://www.ncbi.nlm.nih.gov/pubmed/31329516
http://dx.doi.org/10.1200/JCO.19.00799

Ejemplares similares